Announcement pursuant to Article 19 of Regulation (EU) No. 596/2014
Paiania, 4 February 2025 – Lavipharm S.A., a Pharmaceutical, Chemical, and Cosmetic Products Commercial and Industrial Societe Anonyme (hereinafter the “Company”), announces, in accordance with the provisions of Article 19 of Regulation (EU) No. 596/2014 and following a relevant notification received, that on 3 February 2025, Vasileios Baloumis, Chief Financial Officer (CFO), acquired 20,000 common registered voting shares of the Company with a total value of €16,181.87.